ArticleInfectious diseases and therapy2025
Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05438602 (AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC COVID-19 WHO ARE IMMUNOCOMPROMISED), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An interventional efficacy and safety, phase 2, randomized, double-blind, 3-arm study to investigate nirmatrelvir/ritonavir in nonhospitalized participants at least 12 years of age with symptomatic covid-19 who are immunocompromised
Who cites it
1 citing paper in PubMed.
- Health-related quality of life in immunocompromised adults with mild-moderate COVID-19 treated with nirmatrelvir-ritonavir: results from the randomized, double-blinded EPIC-IC trial.Health and quality of life outcomes · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEPIC-IC was a randomized, double-blind trial comparing the approved 5-day regimen of nirmatrelvir-ritonavir (NMV/r) vs. 10-day and 15-day NMV/r in immunocompromised individuals with mild-to-moderate COVID-19. We describe patient-reported global impressions of illness from EPIC-IC.
methodsIn EPIC-IC, 155 immunocompromised participants received 5-day, 10-day, or 15-day NMV/r (1:1:1). Participants completed the Global Impressions Questionnaire through week 24. Median times to first alleviation and resolution of symptoms and return to usual health and usual activities were estimated using Kaplan-Meier analyses for each treatment arm and post hoc subpopulations with severe vs. non-severe immunocompromise. Five-day arm times were compared vs. 10-day and 15-day arm times.
resultsSymptoms were alleviated after a median 6.0 (95% CI 4.0-9.0) days with 5-day NMV/r, similar to 9.0 (5.0-9.0) days with 10-day NMV/r (p = 0.627) and 10.0 (6.0-11.0) days with 15-day NMV/r (p = 0.528). Symptoms resolved after a median 16.0 (10.0-22.0) days with 5-day NMV/r, similar to 13.0 (9.0-14.0) days with 10-day (p = 0.140) and 13.0 (11.0-21.0) days with 15-day NMV/r (p = 0.471). In the severely immunocompromised subpopulation, symptoms resolved later with 5-day vs. 10-day NMV/r (p = 0.026). Participants returned to usual health after a median 11.0 (6.0-16.0) days with 5-day NMV/r, similar to 9.0 (6.0-13.0) days with 10-day (p = 0.319) and 10.0 (6.0-13.0) days with 15-day NMV/r (p = 0.218), and to usual activities after 10.0 (9.0-15.0) days with 5-day NMV/r, similar to 9.0 (6.0-10.0) days with 10-day (p = 0.102) and 9.0 (5.0-10.0) days with 15-day NMV/r (p = 0.190).
conclusionsTimes to symptom alleviation/resolution and returns to usual health/activities were similar with 5-day vs. extended NMV/r and comparable to those in the EPIC-HR trial. Five-day treatment may be adequate for most immunocompromised individuals, while extended treatment might improve symptom resolution in those with severe immunocompromise; larger studies are needed to confirm these findings.
trial registrationClinicalTrials.gov identifier, NCT05438602.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.